Suppr超能文献

放疗与 BRCA1 突变携带者中腔上皮细胞优先耗竭的关联。

Association of radiotherapy with preferential depletion of luminal epithelial cells in a BRCA1 mutation carrier.

机构信息

Department of Molecular Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, 78245, USA.

出版信息

Exp Hematol Oncol. 2012 Oct 8;1(1):31. doi: 10.1186/2162-3619-1-31.

Abstract

Radiation therapy (RT) after breast conservation therapy has recently been linked with significant reduction in risk of ipsilateral breast cancer among BRCA1 mutation carriers. However, the exact mechanism by which RT reduces incidence of BRCA1-associated cancer remains unclear. Here we studied fresh breast tissue from a BRCA1 mutation carrier who was initially treated with a lumpectomy and RT for a unilateral cancer and two years later chose a prophylactic bilateral mastectomy while remaining cancer-free. Flow cytometry analysis demonstrated a strikingly lower luminal cell population in the irradiated breast as compared to the non-irradiated breast, which was confirmed by immunohistochemistry. Furthermore, the irradiated breast tissue exhibited very low progenitor cell activity in vitro. Given the emerging evidence that BRCA1 tumors originate from luminal progenitor cells, our observations suggest that preferential and long-lasting elimination of luminal ductal epithelium may partly underlie the mechanism of RT-associated reduction in recurrence of BRCA1-associated cancer.

摘要

放射治疗(RT)在保乳治疗后,最近与 BRCA1 突变携带者同侧乳腺癌风险的显著降低有关。然而,RT 降低 BRCA1 相关癌症发病率的确切机制尚不清楚。在这里,我们研究了一位 BRCA1 突变携带者的新鲜乳腺组织,该患者最初接受了单侧癌症的肿块切除术和 RT 治疗,两年后在仍然无癌的情况下选择了预防性双侧乳房切除术。流式细胞术分析表明,与未照射的乳房相比,照射的乳房中腔细胞群明显减少,免疫组织化学进一步证实了这一点。此外,照射的乳腺组织在体外显示出极低的祖细胞活性。鉴于 BRCA1 肿瘤起源于腔前体细胞的新证据,我们的观察结果表明,腔导管上皮的优先和持久消除可能部分解释了 RT 相关降低 BRCA1 相关癌症复发的机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b1c/3514114/2674b7325306/2162-3619-1-31-1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验